- Home
- YGMZ vs LYRA Comparison
YGMZ vs LYRA Comparison
Compare YGMZ & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YGMZ
- LYRA
- Stock Information
- Founded
- YGMZ 2002
- LYRA 2005
- Country
- YGMZ China
- LYRA United States
- Employees
- YGMZ N/A
- LYRA N/A
- Industry
- YGMZ Transportation Services
- LYRA Medical/Dental Instruments
- Sector
- YGMZ Consumer Discretionary
- LYRA Health Care
- Exchange
- YGMZ Nasdaq
- LYRA Nasdaq
- Market Cap
- YGMZ 10.7M
- LYRA 11.3M
- IPO Year
- YGMZ 2020
- LYRA 2020
- Fundamental
- Price
- YGMZ $0.13
- LYRA $5.83
- Analyst Decision
- YGMZ
- LYRA Hold
- Analyst Count
- YGMZ 0
- LYRA 1
- Target Price
- YGMZ N/A
- LYRA $16.00
- AVG Volume (30 Days)
- YGMZ 4.7M
- LYRA 51.1K
- Earning Date
- YGMZ 01-01-0001
- LYRA 11-07-2025
- Dividend Yield
- YGMZ N/A
- LYRA N/A
- EPS Growth
- YGMZ N/A
- LYRA N/A
- EPS
- YGMZ N/A
- LYRA N/A
- Revenue
- YGMZ $40,429,750.00
- LYRA $770,000.00
- Revenue This Year
- YGMZ N/A
- LYRA N/A
- Revenue Next Year
- YGMZ N/A
- LYRA $106.28
- P/E Ratio
- YGMZ N/A
- LYRA N/A
- Revenue Growth
- YGMZ N/A
- LYRA N/A
- 52 Week Low
- YGMZ $0.13
- LYRA $3.81
- 52 Week High
- YGMZ $1.54
- LYRA $37.50
- Technical
- Relative Strength Index (RSI)
- YGMZ 28.14
- LYRA 34.62
- Support Level
- YGMZ $0.13
- LYRA $6.25
- Resistance Level
- YGMZ $0.15
- LYRA $7.30
- Average True Range (ATR)
- YGMZ 0.11
- LYRA 0.52
- MACD
- YGMZ -0.06
- LYRA -0.16
- Stochastic Oscillator
- YGMZ 0.31
- LYRA 0.46
About YGMZ MingZhu Logistics Holdings Limited
MingZhu Logistics Holdings Ltd is a Holding company. Its business activities include trucking services and car owner services. The segments of the company are the trucking business, car owner services business, and liquor distribution business.
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.